INT192684

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.19
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 9.18
Pain Relevance 1.75

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

vs (Mus musculus)
Pain Link Frequency Relevance Heat
Thermal hyperalgesia 21 98.08 Very High Very High Very High
Central grey 231 97.50 Very High Very High Very High
withdrawal 20 92.08 High High
rheumatoid arthritis 78 90.64 High High
antagonist 27 87.00 High High
Inflammation 74 81.24 Quite High
Multiple sclerosis 51 71.04 Quite High
Pain 70 69.88 Quite High
nMDA receptor 33 50.00 Quite Low
Arthritis 7 50.00 Quite Low
Disease Link Frequency Relevance Heat
Infection 87 100.00 Very High Very High Very High
Disease 264 99.84 Very High Very High Very High
Cancer 73 99.52 Very High Very High Very High
Inflammatory Bowel Disease 39 99.30 Very High Very High Very High
Hyperalgesia 27 98.08 Very High Very High Very High
Urological Neuroanatomy 231 97.50 Very High Very High Very High
Recurrence 68 95.72 Very High Very High Very High
Nociception 27 95.04 Very High Very High Very High
Herpes Zoster 9 93.08 High High
Togavirus Infection 14 92.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Comparisons of all variables were conducted for all subjects who had reported WD vs nWD at the time of the survey.
Negative_regulation (reported) of vs
1) Confidence 0.19 Published 2008 Journal The Open Rheumatology Journal Section Body Doc Link PMC2588092 Disease Relevance 0.56 Pain Relevance 0.07
As illustrated in Fig. 5, CFA-treated ipsilateral paws (left) showed a significant decrease in PWL when compared to left paws of control rats (from 12.6 ± 1.2 s to 6.8 ± 0.7 s, n = 10, p < 0.01 vs CFA-injected alone; Fig. 5B).
Negative_regulation (decrease) of vs
2) Confidence 0.11 Published 2009 Journal Mol Pain Section Body Doc Link PMC2803476 Disease Relevance 0.94 Pain Relevance 0.58
l) into the PAG induced a significant increase in PWL in CFA injected rats (ipsilateral: 11.8 ± 1.2 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5B; contralateral: 12.1 ± 1.4 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5C).
Negative_regulation (microinjection) of vs associated with central grey
3) Confidence 0.11 Published 2009 Journal Mol Pain Section Body Doc Link PMC2803476 Disease Relevance 0.89 Pain Relevance 0.54
l) into the PAG (ipsilateral: 11.2 ± 1.1 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5B; contralateral: 11.5 ± 1.6 s, n = 5, p < 0.05 vs saline microinjection, Fig. 5C).


Negative_regulation (microinjection) of vs associated with central grey
4) Confidence 0.11 Published 2009 Journal Mol Pain Section Body Doc Link PMC2803476 Disease Relevance 0.76 Pain Relevance 0.52
Overall survival did not differ in our series for rectal-cancer patients who underwent preoperative vs. postoperative radiotherapy.
Negative_regulation (preoperative) of vs associated with cancer
5) Confidence 0.09 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC1959229 Disease Relevance 1.12 Pain Relevance 0
However the percentage of subjects with severe limitations to running or jumping was considerably reduced compared with the pre-surgical assessment: running, 54% vs 15%; and jumping: 71 vs 31% (Table 4).
Negative_regulation (reduced) of vs
6) Confidence 0.08 Published 2010 Journal The Open Orthopaedics Journal Section Body Doc Link PMC2817880 Disease Relevance 0 Pain Relevance 0
The walking speed increased and the CV of the stride interval decreased during the S-VS on walking as compared to the S-VS off walking.
Negative_regulation (decreased) of S-VS
7) Confidence 0.05 Published 2006 Journal J Neuroengineering Rehabil Section Body Doc Link PMC1471796 Disease Relevance 0.27 Pain Relevance 0
In the PD group, S-VS decreased stride variability (p < 0.002), increased walking speed (p < 0.0001), stride duration (p < 0.01), stride length (p < 0.0002), and cadence (p < 0.03).
Negative_regulation (decreased) of S-VS associated with disease
8) Confidence 0.05 Published 2006 Journal J Neuroengineering Rehabil Section Abstract Doc Link PMC1471796 Disease Relevance 0.35 Pain Relevance 0
13 vs >13 mg/kg) and peginterferon alfa-2a dose reductions (yes vs no).
Negative_regulation (reductions) of vs
9) Confidence 0.05 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.28 Pain Relevance 0
13 vs >13 mg/kg) and peginterferon alfa-2a dose reductions (yes vs no).
Negative_regulation (reductions) of vs
10) Confidence 0.05 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.29 Pain Relevance 0
In contrast, peginterferon alfa-2a dose reduction (yes vs no) was not a predictor of RVR or cEVR.


Negative_regulation (reduction) of vs
11) Confidence 0.05 Published 2010 Journal Journal of Viral Hepatitis Section Body Doc Link PMC2810441 Disease Relevance 0.12 Pain Relevance 0
Vaccine efficacy is defined as percentual risk reduction for clinically significant infection in a vaccinated group vs a control group [71].
Negative_regulation (reduction) of vs associated with infection
12) Confidence 0.04 Published 2010 Journal Rheumatology (Oxford, England) Section Body Doc Link PMC2936949 Disease Relevance 1.45 Pain Relevance 0
Three IPTp clinical trials are currently underway in Benin, Malawi and Tanzania [44-46] and will evaluate SP vs mefloquine[44]; SP alone vs SP plus artesunate[45]; and SP alone vs SP plus azithromycin[46] respectively.
Negative_regulation (evaluate) of vs
13) Confidence 0.04 Published 2007 Journal Malar J Section Body Doc Link PMC1805504 Disease Relevance 0.45 Pain Relevance 0
In addition, natalizumab produced a 92% reduction in gadolinium-enhancing lesions (2.4 vs. 0.2; p<0.001), an 83% reduction in new or enlarging T2-hyperintense lesions (11.0 vs. 1.9; p<0.001) and a 76% reduction in new T1-hypointense lesions (4.6 vs. 1.1; p<0.001) over the two year period.
Negative_regulation (reduction) of vs
14) Confidence 0.03 Published 2010 Journal The Open Neurology Journal Section Body Doc Link PMC3024587 Disease Relevance 1.05 Pain Relevance 0.04
At 4 weeks, the UC-DAI total score was significantly decreased vs baseline in both the 40 mg and 80 mg groups.
Negative_regulation (decreased) of vs associated with inflammatory bowel disease
15) Confidence 0.02 Published 2008 Journal Colorectal Disease Section Abstract Doc Link PMC2659364 Disease Relevance 0.60 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox